Education
About Us
Working with TipRanks
Follow Us
Newton Charles W. Insider Profile
4 Followers
Newton Charles W., CFO at Lyell Immunopharma, holds 172.72K shares in Lyell Immunopharma (Ticker: LYEL), holds ― shares in Coherus Biosciences (Ticker: CHRS), holds 22.63K shares in 2seventy bio (Ticker: TSVT).
Newton Charles W. has not reported sufficient informative transactions and therefore cannot be ranked.
Time Frame
Compare to
Insider Holdings
Insider Roles
Roles that Newton Charles W. holds in companies
Most Profitable Insider Trade
Currently, no data available
The most profitable trade made by Newton Charles W.
Newton Charles W.'s Trading History
Lyell Immunopharma
Feb 26, 2025
CFO
Uninformative Buy
―
$128.33K
Coherus Biosciences
―
Director
―
―
2seventy bio
Jun 12, 2024
Director
Uninformative Buy
―
$60.18K
List of latest transactions for each holding click on a transaction to see Newton Charles W.'s performance on stock
You May Also Like
Newton Charles W. insider profile FAQ
What is the percentage of profitable transactions made by Newton Charles W.?
The percentage of profitable transactions made by Newton Charles W. is ―.
What is the average return per transaction made by Newton Charles W.?
The average return per transaction made by Newton Charles W. is ―.
What stocks does Newton Charles W. hold?
Newton Charles W. holds: LYEL, CHRS, TSVT stocks.
What was Newton Charles W.’s latest transaction?
Newton Charles W. latest transaction was an Uninformative Buy of ―.
What was Newton Charles W.'s most profitable transaction?
Newton Charles W.’s most profitable transaction was an Uninformative Buy of stock on ―. The return on the trade was ―.
What is Newton Charles W.'s role in Lyell Immunopharma?
Newton Charles W.'s role in Lyell Immunopharma is CFO.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.